Product NDC: | 57664-502 |
Proprietary Name: | tizanidine |
Non Proprietary Name: | tizanidine |
Active Ingredient(s): | 2 mg/1 & nbsp; tizanidine |
Administration Route(s): | ORAL |
Dosage Form(s): | TABLET |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 57664-502 |
Labeler Name: | CARACO PHARMACEUTICAL LABORATORIES, LTD. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA076416 |
Marketing Category: | ANDA |
Start Marketing Date: | 20031211 |
Package NDC: | 57664-502-89 |
Package Description: | 150 TABLET in 1 BOTTLE (57664-502-89) |
NDC Code | 57664-502-89 |
Proprietary Name | tizanidine |
Package Description | 150 TABLET in 1 BOTTLE (57664-502-89) |
Product NDC | 57664-502 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | tizanidine |
Dosage Form Name | TABLET |
Route Name | ORAL |
Start Marketing Date | 20031211 |
Marketing Category Name | ANDA |
Labeler Name | CARACO PHARMACEUTICAL LABORATORIES, LTD. |
Substance Name | TIZANIDINE HYDROCHLORIDE |
Strength Number | 2 |
Strength Unit | mg/1 |
Pharmaceutical Classes | Adrenergic alpha2-Agonists [MoA],Central alpha-2 Adrenergic Agonist [EPC] |